Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
复制标题
DOI：
10.1126/science.1158545
复制
发表时间：
2008-08-15
期刊：
影响因子：
56.9
通讯作者：
Kufer, Peter
中科院分区：
文献类型：
--
作者：
Bargou, Ralf;Leo, Eugen;Kufer, Peter
先前的尝试表明，T细胞在癌症免疫疗法中的潜力。在这里，我们报告了一种称为Blinatumomab的双特异性抗体构建体的临床活性，该抗体构建体有可能吸引患者所有细胞毒性T细胞裂解癌细胞。非霍奇金淋巴瘤患者每天低至每平方米0.005毫克的剂量导致血液中的靶细胞消除。首先以0.015毫克的剂量水平观察到部分和完全的肿瘤回归，所有七名患者的剂量水平为0.06毫克，肿瘤退化。布里纳曲霉也导致从骨髓和肝脏中清除肿瘤细胞。与T细胞的抗体似乎具有治疗恶性疾病的治疗潜力。
Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non- Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell- engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.